This May marks the one-year anniversary of the FDA-approval of Radicava, the only FDA-approved ALS treatment option in the last 20 years. Radicava’s developer, Mitsubishi Tanabe Pharma Corporation (MTPC) began researching ALS in 2001 through an interactive clinical platform that spanned 13 years. Following FDA-approval in May of 2017, Radicava became available to people living with ALS in the U.S. in August of last year.
In MTPC’s pivotal clinical trial, people given Radicava experienced a 33 percent slower rate of decline in the loss of physical function, compared to those given a placebo. Since becoming available in the U.S. by Mitsubishi Tanabe Pharma America (MTPA), more than 2,500 people living with ALS in the U.S. have received Radicava.
At the Lois Insolia ALS Clinic at The Les Turner ALS Center at Northwestern Medicine, our clinic staff works to educate people living with ALS and their families about this treatment option.
Atsushi Fujimoto, President, MTPA reflects, “Without a doubt, 2017 was an exciting year with the FDA approval of Radicava. Our goal in the year ahead is to continually help more people with ALS. We are honored to have had the opportunity to serve this community and look forward to continuing our commitment to patients in the years to come.”
